Los Angeles Capital Management’s Ligand Pharmaceuticals LGND Stock Holding History

Los Angeles Capital Management’s Portfolio LGND Stock Details LGND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$31.6K	Sell	100 -5,050	-98%	-$1.19M	﹤0.01%	1628
2026 Q1	$1.03M	Sell	5,150 -5,171	-50%	-$1.02M	﹤0.01%	671
2025 Q4	$1.93M	Buy	10,321 +5,587	+118%	+$1.07M	0.01%	452
2025 Q3	$839K	Buy	4,734 +2,254	+91%	+$335K	﹤0.01%	752
2025 Q2	$282K	Sell	2,480 -61	-2%	-$6.52K	﹤0.01%	1072
2025 Q1	$267K	Sell	2,541 -4,020	-61%	-$455K	﹤0.01%	934
2024 Q4	$703K	Sell	6,561 -529	-7%	-$59.8K	﹤0.01%	723
2024 Q3	$710K	Sell	7,090 -130	-2%	-$13.1K	﹤0.01%	762
2024 Q2	$608K	Buy	+7,220	New	+$575K	﹤0.01%	803
2021 Q3	–	Sell	-3,448	Closed	-$282K	–	1544
2021 Q2	$282K	Sell	3,448 -160	-4%	-$13.3K	﹤0.01%	1414
2021 Q1	$343K	Buy	+3,608	New	+$341K	﹤0.01%	1384
2020 Q3	–	Sell	-3,174	Closed	-$221K	–	1476
2020 Q2	$221K	Buy	+3,174	New	+$201K	﹤0.01%	1375
2020 Q1	–	Sell	-6,508	Closed	-$423K	–	1419
2019 Q4	$423K	Sell	6,508 -10,452	-62%	-$698K	﹤0.01%	1056
2019 Q3	$1.05M	Buy	16,960 +1,267	+8%	+$79.5K	0.01%	794
2019 Q2	$1.12M	Sell	15,693 -6,012	-28%	-$443K	0.01%	811
2019 Q1	$1.7M	Buy	21,705 +9,803	+82%	+$743K	0.01%	699
2018 Q4	$1.01M	Buy	11,902 +4,190	+54%	+$447K	0.01%	741
2018 Q3	$1.32M	Buy	7,712 +3,062	+66%	+$462K	0.01%	777
2018 Q2	$601K	Hold	4,650	–	–	﹤0.01%	1084
2018 Q1	$479K	Buy	4,650 +32	+0.7%	+$3.17K	﹤0.01%	1044
2017 Q4	$394K	Buy	4,618 +1,906	+70%	+$165K	﹤0.01%	1122
2017 Q3	$230K	Buy	+2,712	New	+$215K	﹤0.01%	1217
2016 Q2	–	Sell	-3,092	Closed	-$207K	–	1265
2016 Q1	$207K	Buy	+3,092	New	+$188K	﹤0.01%	1050

Other funds holding LGND

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Jupiter Topco New York $245B AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

CAM

Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Los Angeles Capital Management's LGND Position: Q2 2026 in Review

Los Angeles Capital Management reduced its Ligand Pharmaceuticals (LGND) stake by 98% in Q2 2026, selling an estimated $1.19M and leaving 100 shares worth $31.6K. The position accounts for ﹤0.01% of the portfolio, ranked #1628.

Los Angeles Capital Management first reported a position in LGND in Q1 2016 and has held it in 23 quarters since. The position peaked at $1.93M in Q4 2025. 414 funds tracked by Wall St. Rank hold LGND as of Q2 2026.

Los Angeles Capital Management held 100 shares of Ligand Pharmaceuticals worth $31.6K as of Q2 2026.
Los Angeles Capital Management sold 5,050 Ligand Pharmaceuticals shares in Q2 2026, an estimated $1.19M.
Ligand Pharmaceuticals made up ﹤0.01% of Los Angeles Capital Management's portfolio in Q2 2026, its #1628 holding.
Los Angeles Capital Management first reported a position in Ligand Pharmaceuticals in Q1 2016 and has held it in 23 quarters since.
Los Angeles Capital Management's Ligand Pharmaceuticals position peaked at $1.93M in Q4 2025.
414 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q2 2026.

Based on Los Angeles Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.